senecabiomedicalpksenecabiomedicalpk Facebook ad: “Retatrutide, Research Overview”
Ran for 4 days, from March 4 to March 8, 2026, the last day Crush saw it.
Run by senecabiomedicalpk on Instagram. Crush is not the advertiser and does not verify its claims. See this ad in Meta's Ad Library(opens in a new tab)
Want an ad like this for your product?
Crush makes new ad images for your product from this ad: your logo, your product photo, your offer.
Trials from $19.95 USD, then $79.95 USD a month. Cancel anytime.
About this ad
- Meta Ad Library ID
- 1436064651556211
- Platforms
- Relaunches
- 0
Ad text
Retatrutide – Research Overview Retatrutide is an advanced triple receptor agonist (GLP-1 / GIP / Glucagon) currently being explored in scientific research for its potential metabolic applications. Researchers are studying its role in body composition, appetite signaling pathways, energy regulation, and metabolic markers. Preclinical and clinical investigations are evaluating its potential influence on: • Body fat reduction mechanisms • Appetite regulation pathways • Metabolic efficiency • Muscle mass preservation during weight management research • Energy expenditure processes • Liver fat and metabolic health markers As a triple agonist, Retatrutide is designed to interact with multiple metabolic receptors, making it a subject of growing interest in obesity and metabolic research models. This product is intended strictly for laboratory and research purposes. Website: https://www.senecabiomedical.com/ For more information Message us on WhatsApp at +92 310 6110134 https://wa.me/923106110134 This content is for educational and research information only. It is not medical advice and not intended for human consumption. #Retatrutide #MetabolicResearch #GLP1 #GIP #Glucagon #TripleAgonist #PeptideResearch #LaboratoryUseOnly #ResearchPeptides #MetabolismStudy #ScientificResearch #SenecaBiomedical #BiotechResearch #WeightManagementResearch #NotMedicalAdvice
